

**Adult CIRB – Early Phase Emphasis
Meeting Agenda**

Tuesday, January 16, 2018

I Initial Review

10129, A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors (Protocol Version Date 11/21/17)

II Initial Review

NRG-GY013, A pre-operative window pharmacodynamics trial of Triapine (NSC#663249) in uterine corpus serous adenocarcinoma (Protocol Version Date 11/15/17)

III Continuing Review

9974, A phase II study of olaparib plus cediranib in combination with standard therapy for small cell lung cancer (Protocol Version Date 10/18/17)

IV Continuing Review

10021, A Phase 2 Study of MEDI4736(durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC (Protocol Version Date 08/31/17)

V Continuing Review

9608, A Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 inhibitor, and Sorafenib (Nexavar) in Patients with Relapsed or Refractory Solid Organ Tumors (Protocol Version Date 04/28/17)

VI Continuing Review

9914, A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors (Protocol Version Date 09/11/17)

VII Continuing Review

9952, Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined with Whole Brain Radiotherapy (WBRT) in Patients with Brain Metastases from Non-Small Cell Lung Cancer (NSCLC) (Protocol Version Date 07/26/17)

VIII Continuing Review

9924, A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL) (Protocol Version Date 11/13/17)

IX **Continuing Review**

10030, A phase 1 study of blinatumomab in combination with checkpoint inhibitor(s) of PD-1 (nivolumab) or both PD-1 (nivolumab) and CTLA-4 (ipilimumab) in patients with poor-risk, relapsed or refractory CD19+ precursor B-lymphoblastic leukemia (Protocol Version Date 09/05/17)

X **Continuing Review**

EA2142, Randomized Phase II Study of Platinum and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas (Protocol Version Date 12/06/16)
